Please upgrade your browser.
NCCN has added everolimus (Afinitor(R), Novartis) to the NCCN Guidelines for Kidney Cancer as a recommended treatment for patients with renal cell carcinoma whose disease has progressed after treatment with kinase inhibitors.
Of particular interest are the preclinical findings supporting potential new combinations of ASA404 with targeted therapies in lung and renal cancers.
The company`s lead product, AV-951, a potential best-in-class triple VEGF receptor inhibitor, is completing Phase 2 clinical development in patients with metastatic renal cell cancer and is expected to enter Phase 3 development in 2009.
Studies show survival after surgery for melanoma, lung, renal cell, breast and colon cancer metastases ranges from a median of seven months for melanoma patients to a year for breast and lung cancer.
He spent $50,000 to get a personal medical symposium - with four of the best kidney cancer experts in the world - immediately organized.
Government-sponsored comparative-effectiveness research virtually guarantees that such individualized care will vanish. Doctors and patients alike should be alarmed.
Stormtrooper gives kidney to Imperial comrade.
Beware of geeks bearing formulas. That's the lesson most of us have learned from the financial crisis. The "quants" who devised the risk models that induced so many financial institutions to buy mortgage-backed securities thought they had reduced risk down to zero.
Congress and the president need only look to their own health insurance program as a model for dealing with the tens of millions of Americans who lack health insurance.
The Canadian Oncology Societies and the Canadian Association of Medical Oncologists continue their monthly series of interactive webcasts.
|Powered by NeonCRM|